ライフサイエンスコーパス: tumor volume

1 icient mice ( approximately 66% reduction in tumor volume).

2 es were a positive, linear function of total tumor volume.

3 Both formulas tended to overestimate the tumor volume.

4 mages and caliper were used to determine the tumor volume.

5 ere generated from pixel ADCs from the whole tumor volume.

6 en if these cells comprise a minority of the tumor volume.

7 itinib monotherapy was tested for effects on tumor volume.

8 ed with age, baseline PSA, Gleason score, or tumor volume.

9 trations showed significant correlation with tumor volume.

10 nse to anti-VEGF treatment, the reduction in tumor volume.

11 were expressed as a percentage of the total tumor volume.

12 V50% were unsuccessful in segmenting primary tumor volume.

13 beta-1,4-GalT-V), showed marked reduction in tumor volume.

14 ion to Tam as demonstrated by a reduction in tumor volume.

15 The imaging signal intensity correlated with tumor volume.

16 stream effectors and that precede changes in tumor volume.

17 ompletely avoid dose buildup in front of the tumor volume.

18 ction in fBV in the absence of any change in tumor volume.

19 -500 mmol/L and injection volumes 20%-80% of tumor volume.

20 with 2j showed a more than 50% reduction in tumor volumes.

21 3 patients demonstrated a reduction in uveal tumor volumes.

22 iregional (contrast-enhanced and unenhanced) tumor volumes.

23 ; P < .0001), rendered the smallest relative tumor volume (0.65 mm(3) +/- 0.15, P < .0001) and relati

24 ; P < .0001), rendered the smallest relative tumor volume (0.65 mm(3) +/- 0.15, P < .0001) and relati

25 xenografts, as well as the smallest relative tumor volume (0.68 mm(3) +/- 0.13, P < .05) and relative

26 xenografts, as well as the smallest relative tumor volume (0.68 mm(3) +/- 0.13, P < .05) and relative

27 Mean HCC tumor volumes 10 days after therapy were 1.68 cm(3) +/-

28 blished clinical imaging biomarker of active tumor volume ([(18)F]FET) in conjunction with MRI.

29 with ZD6126 induced a 45% reduction in mean tumor volume 24 hours after treatment (P < .005; P < .00

30 y larger in (18)F-FET PET than in rCBV maps (tumor volume, 24.3 +/- 26.5 cm(3) vs. 8.9 +/- 13.9 cm(3)

31 A greater decrease in lung tumor volume (-37.2% vs. -27.6%) was associated with a b

32 .0005), resulting in a striking reduction in tumor volume (50% smaller) 2 months following treatment.

33 mage analysis and total (68)Ga-DOTATATE-Avid tumor volume ((68)Ga-DOTATATE TV) was determined.

34 5% CI: 6%, 65%) and a 127% increase in total tumor volume (95% CI: 12%, 358%).

35 e above an SUVmax of 10 (TLF10) and fluoride tumor volume above an SUVmax of 10 (FTV10).

36 All patients received IGRT to reduced tumor volumes according to strict protocol guidelines.

37 ification according to overall and enhancing tumor volume achieved significance (HR, 1.8; 95% CI: 0.9

38 Baseline lung tumor volume addressed with (68)Ga-DOTA-E-[c(RGDfK)](2)

39 visualization and improved quantification of tumor volume after bevacizumab treatment.

40 ds between the volume of tumor and change in tumor volume after therapy on CE T1-weighted subtraction

41 Therapeutic studies showed 80% reduction of tumor volumes after 28 d demonstrating significant inhib

42 ivity concentrations, such as those found in tumor volumes, allowing for adequate tumor (90)Y PET/CT

43 erobserver agreement was excellent for whole-tumor volume analysis (range, 0.91-0.95) but was only mo

44 The combination of whole tumor volume and ADC can be used for prediction of tumor

45 of cSCC cells in vitro and reduced xenograft tumor volume and angiogenesis in vivo.

46 by using PET/CT with (18)F-FDG to determine tumor volume and by monitoring survival.

47 We observed an increase in tumor volume and C-choline uptake between days 5 and 18.

48 sizes from experiments assessing changes in tumor volume and conducted subgroup analyses based on pr

49 Increased tumor volume and decreased histologic response to chemot

50 Levels of ctDNA were highly correlated with tumor volume and distinguished between residual disease

51 a preclinical model of PDAC reduces primary tumor volume and eliminates metastatic disease.

52 C PDX models showed significant reduction in tumor volume and enhanced delay in tumor regrowth follow

53 resulting in an average reduction of 77% in tumor volume and eradication of some tumors.

54 poxia; nor did we see an association between tumor volume and hypoxia.

55 Immunohistochemistry revealed reduced tumor volume and increased cell death in ErPC3-treated a

56 while silencing of LIN28 expression reduces tumor volume and increases tumor differentiation, indica

57 umors in a subcutaneous murine model reduced tumor volume and induced tumor cell death.

58 ncement serves as an imperfect surrogate for tumor volume and is influenced by agents that affect vas

59 containing 5mg of 5-ALA did not suppress the tumor volume and led to tumor growth comparable to the u

60 Unexpectedly, primary tumor volume and liver metastases were increased in 5-LO

61 Contrast-enhanced tumor volume and longest axis length of tumor were stron

62 raits and 2 conventional features (metabolic tumor volume and maximum SUV).

63 molecules is frequently heterogeneous in the tumor volume and may be driven by hypoxia and HIF-1alpha

64 ats (n = 6) and correlated with histological tumor volume and norepinephrine transporter (NET) expres

65 are presented, including computed tomography tumor volume and perfusion, dynamic contrast material-en

66 Notably, tumor volume and pulmonary metastatic burden after ortho

67 on of detection, quantitative measurement of tumor volume and quantitative follow-up of the tumor dev

68 d median values were obtained by using whole-tumor volume and single-section ROI analyses.

69 rmance of IVIM parameters derived from whole-tumor volume and single-section ROIs for prediction of h

70 o mean normal-liver SUV, and score combining tumor volume and T SUV max (CT/(18)F-FDG PET score).

71 ted measure of heterogeneity is dependent on tumor volume and that measurement of heterogeneity is ab

72 quantification metrics, including metabolic tumor volume and total lesion glycolysis (TLG) with diff

73 uptake measures such as metabolically active tumor volume and total lesion glycolysis (TLG).

74 No significant difference in tumor volume and TVR was found among the six MR imaging

75 nitiating capacity of TNBC cells and reduced tumor volume and viability when administered simultaneou

76 enotypic traits, such as biomass production, tumor volume and viral abundance, undergoes a complex pr

77 ated mice correlated with subsequent reduced tumor volume and was a predictive biomarker of response.

78 nistration of RNase1 but not DNase decreased tumor volume and weight.

79 Contrast-enhancing tumor volumes and change in volumes as a response to the

80 nes were performed and effects on pancreatic tumor volumes and hepatic and pulmonary metastases deter

81 agreement between PET- and histology-derived tumor volumes and intra- and interobserver agreement of

82 XP3 expression was associated with increased tumor volumes and poor prognosis in PDAC especially comb

83 using histogram analysis derived from whole-tumor volumes and single-section regions of interest (RO

84 mall cell lung cancer, but in the esophageal tumors, volume and heterogeneity had less complementary

85 BG and SUV(mean)/BG, respectively], biologic tumor volume) and dynamic time-activity curves, includin

86 or metabolism and volume (SUVmean, metabolic tumor volume) and increase in healthy splenic metabolism

87 of the T1ab cohort, 61% of the cohort total tumor volume, and 75% of distant recurrences.

88 increased intratumoral gemcitabine, reduced tumor volume, and a 57% increase in survival compared to

89 ed as xenografts in mice similarly decreased tumor volume, and expression of a lentivirus blocking NG

90 or receptor type 2 (VEGFR2) phosphorylation, tumor volume, and histopathologic changes.

91 sess MR and fluorescence imaging results and tumor volume, and one-way analysis of variance was used

92 lesions and normal tissue, total functional tumor volume, and SSTR volume (functional tumor volume m

93 SUVmax, SUVmean, metabolic tumor volume, and total lesion avidity were obtained for

94 The SUVmax, SUVmean, metabolic tumor volume, and total lesion avidity were obtained for

95 , and mean (SUV(mean)), metabolically active tumor volume, and total lesion glycolysis (TLG).

96 zed uptake value [SUV], metabolically active tumor volume, and total lesion glycolysis [TLG]), at bas

97 neity, standardized uptake values, metabolic tumor volume, and total lesion glycolysis were measured

98 n SUV, maximum SUV, and peak SUV), metabolic tumor volume, and total lesion glycolysis.

99 SUVmean, SUVpeak, TLG, metabolically active tumor volume, and tumor-to-blood and -liver ratios were

100 ke value as ratio to background and biologic tumor volume; and dynamic analysis of intratumoral (18)F

101 SUVmean; size-incorporated SUVmax; metabolic tumor volume; and total lesion glycolysis.

102 The average tumor volume as determined by PET/CT with (64)Cu-TP3805

103 Brain tumor volume assessment is a major challenge.

104 BNCT vs. control mice (only 424% increase in tumor volume at 14 d post irradiation vs. 1551% in untre

105 cediranib induced a 54% or 20% reduction in tumor volume at 48 hours, respectively (P < .005 and P <

106 Compared with controls, median relative tumor volume at day 23 after injection was reduced by 55

107 ith tumor metabolism, but not with metabolic tumor volume at regional or distant levels, suggests tha

108 We did not observe a difference in tumor volume at the start of the treatment, nor in HER2

109 fference compared to vehicle control despite tumor volume being reduced to levels similar to those re

110 eous tumors, with significant differences in tumor volumes being observed from day 7 after therapy on

111 Inclusion of tumor volumes below 45 cm(3) can profoundly bias compari

112 Concordance for metabolic tumor volume between (18)F-fluciclovine and (18)F-FDG wa

113 or-to-brain-ratio [TBRmax/TBRmean], biologic tumor volume [BTV], and time-activity curves with minima

114 atment and defined as a reduction of >70% in tumor volume by 3 months.

115 combined, it increased the apparent overall tumor volume by 30%; however, volumes remained small (me

116 th only 1 mouse reaching 5 times the initial tumor volume by 60 d after treatment, compared with a me

117 olony formation by up to 59%, and diminished tumor volume by 60% in a human melanoma murine xenograft

118 established murine and human STSs decreased tumor volume by almost two-thirds and cell proliferation

119 Estimation of tumor volume by PET of noninfiltrating brain tumors was

120 t changes in pathophysiology associated with tumor volume can selectively change tumor uptake of nano

121 ough there were no detectable differences in tumor volume, cell density, or apoptosis rate between gr

122 on (ADC3D) was significantly correlated with tumor-volume change until day 11, but the significant co

123 etween ADC change for 7 days (ADC7D) and the tumor-volume change was observed until day 18.

124 ADC3D was significantly correlated with the tumor-volume change, but the higher significance was obs

125 Tumor volume changes measured by magnetic resonance imag

126 The median and range for primary tumor volume (cm(3)) at baseline on (18)F-FDG were 28 an

127 group showed 5.49 and 3.25 fold reduction in tumor volume compared to Nos and DTX alone groups, respe

128 g adenocarcinoma cells resulted in decreased tumor volume compared to vehicle control; however, while

129 with PM were older (P < .001) and had larger tumor volumes compared with nonmetastatic patients (P <

130 4 of 39), partial response was achieved, and tumor volume decreased from a mean value +/- standard de

131 After initial treatment, tumor volume decreased in 53%, stabilized in 27%, and pr

132 nib resulted in confirmed partial responses (tumor volume decreases from baseline of >/=20%) in 17 of

133 Changes in tumor volume defined on CT did not correlate with overal

134 The median MATV metabolically active tumor volume derived with 50% threshold of mean standard

135 n all PET/CT scans, conventional parameters (tumor volume, diameter, maximum and mean standardized up

136 ncentration and magnitude of the decrease in tumor volume did not differ between oligodendrogliomas t

137 ding SUV, proliferative volume, or metabolic tumor volume, did not correlate with outcome.

138 CAR T cells led to significant regression in tumor volume due to enhanced CAR TIL infiltrate, decreas

139 nships between study design and experimental tumor volume effect sizes.

140 By tumor volume endpoint analysis, these mouse tumors respo

141 In contrast, tumor volume estimation by PET of infiltrating brain tum

142 trahepatic (18)F-fluoroethylcholine positive tumor volume (FEC-PTV) and tumor-to-background ratio wer

143 stable disease or better, and had decreased tumor volume following treatment.

144 The average tumor volumes for (18)F-FET uptake and increased Cho/NAA

145 Functional tumor volume (FTV), computed from MR images by using enh

146 haracteristics (longest diameter, functional tumor volume [FTV], peak percentage enhancement [PE], pe

147 hs before randomization, and 33% had hepatic tumor volumes greater than 25%.

148 Clinically significant tumors (tumor volume > 0.5 mL) were identified at whole-mount st

149 y with maximum standardized uptake value and tumor volume (hazard ratio, 1.5 and 2.0, respectively; P

150 In vivo, AUY922 showed decrease in tumor volume in 36.4% of rats (control = 9.4%), increase

151 ular deficits produced a twofold decrease in tumor volume in collagen VI-null mice, confirming that c

152 umors that were 2,982% +/- 2,834% of initial tumor volume in control animals) by day 23.

153 e basis of tumour incidence, body weight and tumor volume in DMBA-induced rats.

154 d decreases neovasculature in HUVEC and also tumor volume in EAT mouse models.

155 LX3397 resulted in a prolonged regression in tumor volume in most patients.

156 strate the inhibition of gene expression and tumor volume in mouse xenografts.

157 the overall size of mammospheres and reduced tumor volume in nude mice.

158 of (68)Ga-DOTATATE PET/CT-based analysis of tumor volume in patients with NETs.

159 The uptake of (111)In-RGD2 followed tumor volume in studies featuring antiangiogenic therapy

160 t-enhancement volumes on MRI (Gd-volume) and tumor volumes in (18)F-FET PET images with a tumor-to-br

161 agreement between PET- and histology-derived tumor volumes in an orthotopic glioblastoma rat model wi

162 this compound markedly diminishes the brain tumor volumes in both subcutaneous and intracranial mode

163 06 and MIA-690 and decreased 22Rv1 xenograft tumor volumes in mice by 63% after 3 wk (P < 0.05).

164 ple, fast, and accurate method of estimating tumor volumes in the clinical setting, suggesting that t

165 reover, 6f showed a significant reduction in tumor volumes in vivo in pancreatic cancer xenografts.

166 uded partial remission (>/= 50% reduction in tumor volume) in five dogs and stable disease (<50% chan

167 five dogs and stable disease (<50% change in tumor volume) in four dogs.

168 l and a 95-99% reduction in the mesothelioma tumor volume, in comparison with vehicle-treated mice.

169 the tumor growth was vastly diminished (186% tumor volume increase at 14 d).

170 Disease progression (tumor volume increase from baseline of >/=20%) has not b

171 Mean MRI tumor volume increased by 109.2% in controls (n = 32) an

172 llulose-ethanol injections of one-fourth the tumor volume induced complete regression in 100% of tumo

173 tions of either four times or one-fourth the tumor volume induced complete regression of 33% and 0% o

174 es was effective, resulting in a significant tumor volume inhibition of DMPM xenografts (range, 58-75

175 Brain tissue was analyzed for tumor volume, invasiveness, hypoxia, vascular density, p

176 Total tumor volume is a good predictor of successful downstagi

177 Typically, the tumor volume is computed on a slice-by-slice basis using

178 the curve describing the probability a given tumor volume is large enough to adequately sample the un

179 uation of therapeutic response by changes in tumor volume is misleading, as volume changes reflect th

180 Median time to tumor progression (tumor volume larger than at day 0) was 3 d for controls,

181 ids, is significantly enriched only in small tumors (volume < 5.7 cm (3)).

182 gnostic significance of metabolically active tumor volume (MATV) measurements applied to (18)F-fluoro

183 images, such as SUVmax, metabolically active tumor volume (MATV), total lesion glycolysis, and, more

184 n and dependence on the metabolically active tumor volume (MATV), which has already been shown to be

185 MATV metabolically active tumor volume measured with 50% of SUVhp mean SUV of a sp

186 ally) or GCV (20 mg/kg) for 9 d, followed by tumor volume measurement.

187 ces derived from whole-body summation of PET tumor volume measurements (i.e., net MATV and net TLA) w

188 by the World Health Organization (WHO) with tumor volume measurements as the standard of reference a

189 ors, and CT imaging improved the accuracy of tumor volume measurements.

190 segmentations per MATV metabolically active tumor volume method.

191 s evaluated for 19 MATV metabolically active tumor volume methods with feasibility of greater than 95

192 ted that the parameters metabolically active tumor volume (MTV) and total lesion glycolysis (TLG) are

193 is pilot study was to determine if metabolic tumor volume (MTV) and total lesion glycolysis (TLG) cou

194 tomography (PET-CT) scans, such as metabolic tumor volume (MTV) and total lesion glycolysis (TLG), wo

195 Metabolic tumor volume (MTV) and total lesion glycolysis were meas

196 ility of these metrics, as well as metabolic tumor volume (MTV) and total uptake of choline in the le

197 evaluated the prognostic value of metabolic tumor volume (MTV) in patients with anal cancer treated

198 In the PET images, the metabolically active tumor volume (MTV) of the primary tumor was delineated w

199 6668/RTOG 0235, high pretreatment metabolic tumor volume (MTV) on (18)F-FDG PET was found to be a po

200 max) measurements, a global breast metabolic tumor volume (MTV) was delineated using a semiautomatic

201 max and SUVmean, respectively) and metabolic tumor volume (MTV) with a threshold of 40%, 50%, and 60%

202 tandardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) wa

203 d uptake value (SUV), maximum SUV, metabolic tumor volume (MTV), and total lesion glycolysis (TLG) we

204 tandardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) we

205 SUVmean, respectively) for tumor, metabolic tumor volume (MTV), and total lesion glycolysis (TLG).

206 of all the MTVs and summation of individual tumor volume multiplied by its mean SUV, respectively.

207 al tumor volume, and SSTR volume (functional tumor volume multiplied by mean SUV) were investigated f

208 d by a high propensity to metastasize at low tumor volumes necessitating the need for effective drug

209 s of avidity and volume (including metabolic tumor volume), nodal SUVmax, and our new concepts of mN

210 18)F-FLT PET was conducted before changes in tumor volume occurred.

211 0.9 years; range, 3.0 to 18.5) with a median tumor volume of 1205 ml (range, 29 to 8744) received sel

212 dose ranged from 50-65 Gy treating a median tumor volume of 3.6 ml (range, 0.3-11.6 ml).

213 down regulated with apoptosis in ~27% of the tumor volume of doxorubicin-resistant human HCC after a

214 the calculation method (sampling schemes and tumor volume of interest).

215 nuing through the end of the study, the mean tumor volume of the FUS+trastuzumab group was significan

216 After 25 days, the final tumor volumes of the mice varied from 12 mm(3) to 62 mm(

217 >/= 7) or who have significant increases in tumor volume on subsequent biopsies should be offered ac

218 hough there was no significant difference in tumor volume on the day of imaging, in the high-uptake g

219 Later, the two readers in consensus measured tumor volume on the first and last study to calculate tu

220 omputer simulation to isolate the effects of tumor volume on the image local entropy.

221 ere compared with the standard of reference (tumor volume) on the basis of RECIST, COG, and WHO thera

222 that the (18)F-FDG PET/CT-derived metabolic tumor volume or total lesion glycolysis, acquired after

223 in lesion count, lesion SUV, Ki, functional tumor volume, or SSTR volume between (68)Ga-DOTATOC and

224 importantly, a significant reduction of the tumor volume over 4 days following administration (p<0.0

225 sule in mice, revealed a 30-fold increase in tumor volume over a period of 26 days and this was accom

226 on of tumor growth resulted in a decrease in tumor volume over a subsequent course of 4 weeks.

227 -drug PEG-b-PCL micelles dramatically reduce tumor volumes over paclitaxel and vehicle controls.

228 Treated rats had reduced tumor volume (p < 0.01), reduced proliferation (Ki-67 st

229 ation tumor pain correlated with preablation tumor volume (P = .02) and pathologic fracture (P = .01)

230 significantly greater reduction in metabolic tumor volume (P = 0.03) and total lesion glycolysis (P =

231 published in vivo measurements of xenograft tumor volume, producing a model that accurately predicts

232 Volumetric parameters, that is, PSMA-derived tumor volume (PSMA-TV) and total lesion PSMA (TL-PSMA),

233 -induced changes in native T1 and changes in tumor volume (r = 0.56; P < .005).

234 (123)I-MIBG uptake (r = 0.91), histological tumor volume (r = 0.68), and NET expression (r = 0.50).

235 Animal model showed significant decrease of tumor volume, rate of metastasis, and mortality of sever

236 with manual tracing of each section, and the tumor volume ratio (TVR) was calculated.

237 gation, and visualized over segmented 3D MRI tumor volume reconstruction.

238 maging outcomes consisted of six responders (tumor volume reduction >90%) and five partial responders

239 Those with tumor volume reduction more than 75% received reduced in

240 Tumor volume reduction was an independent prognostic par

241 lar hemangioblastoma, octreotide resulted in tumor volume reduction, symptom stabilization, and tumor

242 ed mice were imaged prior to therapy-induced tumor volume reduction.

243 ound to correlate well with subject-specific tumor volume reduction.

244 be formed that correlated exponentially with tumor volume reduction.

245 searched for all animal experiments testing tumor volume response to sorafenib monotherapy in any ca

246 relation analysis between [Pi], pO2, pHe and tumor volumes reveal an association of high [Pi] with ch

247 MATV metabolically active tumor volume s were defined semiautomatically with 27 va

248 acene (DMBA)-induced breast cancer decreased tumor volume significantly without affecting the body we

249 ination therapy resulted in smaller relative tumor volume than chemotherapy only and RF hyperthermia

250 ET shows considerably higher TBRs and larger tumor volumes than rCBV maps.

251 zation, with the aim of reducing the primary tumor volume, the effect on metastases is often ignored.

252 re, in rCBV maps and in (18)F-FET PET scans, tumor volumes, their spatial congruence, and the distanc

253 NT61 inhibited tumor formation and decreased tumor volume; this effect was partially blocked by the a

254 und that growth-induced stress is related to tumor volume through a biexponential relationship.

255 ET/CT combined with baseline total metabolic tumor volume (TMTV) could detect early relapse or refrac

256 the prognostic impact of the total metabolic tumor volume (TMTV) measured at baseline with [(18)F]flu

257 prognostic value of baseline total metabolic tumor volume (TMTV) measured on (18)F-FDG PET/CT with ad

258 dized uptake value [SUVmax], total metabolic tumor volume [TMTV]).

259 ng the influence of baseline total metabolic tumor volume (TMTV0) on rituximab PK and of TMTV0 and ri

260 Here, we varied tumor volume to determine whether cancer pathophysiology

261 tumors (500 mm(3)), compound 15 reduced the tumor volume to one-fifth of the starting volume at a do

262 ables, tumor characteristics including total tumor volume (TTV) and up-to-7 criteria were recorded.

263 s according to the previously proposed total tumor volume (TTV; </=115 cm(3) )/alpha-fetoprotein (AFP

264 alue (SUVmax), mean SUV (SUVmean), metabolic tumor volume (TV), and total lesion glycolysis of primar

265 o-actual dose ratio ([Formula: see text]) in tumor volumes (TVs) and nontumor volumes (NTVs) for glas

266 e calculated, as well as PET-segmented gross tumor volumes using visual delineation (GTVVIS) and oper

267 The accurate tumor volume values provided by these formulas may help

268 information with histogram quantification of tumor volumes, volume ratios, apparent diffusion coeffic

269 Median gross tumor volume was 117.0 mL (range, 1.3 to 1,913.4 mL).

270 By PET, the mean U87MG tumor volume was 35.0 mm3 using 18F-FDG and 34.1 mm3 wit

271 n paclitaxel was delivered through CD133NPs (tumor volume was 518.6+/-228 vs. 1370.9+/-295mm(3) for f

272 COVA was applied to gauge how well the total tumor volume was a predictor for the ADC and (18)F-FDG,

273 Tumor volume was also calculated.

274 Total tumor volume was an independent predictor of successful

275 In drug-resistant xenografts, tumor volume was decreased 2.33 and 1.41 fold in xenogra

276 group 1, but only 1 week for group 2, while tumor volume was measured by caliper twice weekly.

277 In these mice, tumor volume was significantly reduced by combinational

278 and SU5416 decreased tumor vascular density, tumor volume was unaffected.

279 ent between PET- and histology-derived U87MG tumor volumes was achieved with 11C-MeAIB, MAP3D reconst

280 quantification of the overall and enhancing tumor volumes was performed in each patient.

281 The mTLV (calculated as TLV - tumor volume) was compared with the eTLV (calculated as

282 SED showed ~30-59% tumor volume/weight reduction in H1650 tumor model compa

283 ers and patients with a higher baseline lung tumor volume were more likely to have a higher progressi

284 SUV(max)/BG, SUV(mean)/BG, and biologic tumor volume were significantly higher in WHO IV than in

285 alue, total lesion glycolysis, and metabolic tumor volume were used.

286 Corresponding T87 tumor volumes were 122.1 mm3 using 18F-FDG, 118.3 mm3 wi

287 mg/kg intraperitoneally daily for 10 d), and tumor volumes were assessed with caliper measurements.

288 Tumor volumes were automatically delineated, and heterog

289 - 2.63 vs. 2.37 +/- 0.32; P < 0.001) whereas tumor volumes were comparable.

290 Gross tumor volumes were defined on T2-weighted MR images, and

291 Tumor volumes were delineated manually, and the input fu

292 Tumor volumes were recorded throughout the dosing period

293 Tumor volumes were significantly larger in (18)F-FET PET

294 4A1 shRNA resulted in a drastic reduction in tumor volume when mice were subjected to vitamin D3 supp

295 se in large tumors), parallels the growth in tumor volume, whereas pulmonary artery perfusion remaine

296 For PEM, the tumor volume with (64)Cu-TP3805 was 113% +/- 37% of that

297 ubthresholding of these contours to give the tumor volume with standardized uptake value >/=2.5.

298 of the maximum standardized uptake value and tumor volume, with concordance indexes of 0.67 and 0.64,

299 on results in a significant reduction of the tumor volume without evident side effects.

300 (three-ROIs), single-section (SS), and whole-tumor volume (WTV) methods in 62 patients with locally a